Subpopulations (%) | Patients with RMS (unfavorable tumor localization) | Control group | Р |
CD3+ HLADR+ | 40.1 ± 6.9 (n = 12) | 12.5 ± 2.0 (n = 12) | 0.001 |
CD8+ HLADR+ | 32.5 ± 7.1 (n = 8) | 8.9 ± 1.4 (n = 11) | 0.001 |
CD3+ CD4+ | 30.3 ± 3.1 (n = 11) | 39.3 ± 2.8 (n = 14) | 0.046 |
Leu8+ CD4+ | 16.2 ± 4.3 (n = 8) | 33.5 ± 4.7 (n = 10) | 0.017 |
γδTCR-Т cells | 16.7 ± 2.1 (n = 8) | 9.6 ± 1.5 (n = 10) | 0.013 |